Will Pricing For Gilead’s Sovaldi Set A Ceiling In HCV, Lead To A Price War?
Gilead’s wholesale acquisition cost of $1,000-a-day for Sovaldi met with immediate backlash, as well as foreboding comments from a leading PBM. Observers anticipate a possible pricing war between Gilead and other companies developing new regimens for HCV.
You may also be interested in...
The view from 2020: Scrip looks back at the most successful commercial launches of the decade.
As India gets set to resume COVID-19 vaccine diplomacy from October, a new rule which will require Indians visiting UK who are fully vaccinated with AstraZeneca partner Serum Institute’s vaccine to undergo quarantine has sparked a row. Meanwhile, Indian companies await a nod from the WHO for wider acceptance of their COVID-19 vaccines.
Six supplement categories based on submission content will be created with review goals between three and 10 months.